1. IDYA will participate in Jefferies Global Healthcare Conference on June 4. 2. CEO Yujiro Hata to speak at Goldman Sachs conference on June 9. 3. Live audio webcasts will be available for both conferences. 4. IDEAYA focuses on precision medicine and targeted therapeutics development. 5. Company emphasizes synthetic lethality in drug discovery efforts.
Participation in notable healthcare conferences can enhance investor visibility and confidence, similar to past events boosting stocks of biotech companies post-conferences.
The article indicates significant events that could attract investor attention, enhancing stock visibility.
Immediate impact expected as upcoming conferences create short-term investor interest and potential stock movement.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Wednesday, June 4th, 2025 at 8:10 AM ET
Monday, June 9th, 2025 at 10:40 AM ET
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event.
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
[email protected]
SOURCE IDEAYA Biosciences, Inc.